How AI Research Agents Are Transforming Life Sciences Intelligence
In the high-stakes arena of drug development and clinical evidence generation, the bottleneck is no longer the availability of data; it is the speed of synthesis. For the past decade, life sciences organizations have invested billions into digitizing real-world data (RWD), scaling bioinformatics pipelines, and implementing Natural Language Processing (NLP) to parse the ever-expanding […]
When Good Intentions Meet Bad Data: Why Pharma Patient Research Projects Go Off Track
Pharmaceutical companies invest billions to understand patients. Market research teams conduct thousands of surveys and collect patient-reported outcomes with the genuine intent of developing better therapies and launching products that meet real patient needs. Yet despite these investments, six out of ten pharmaceutical drug launches underperform in their first year.1 Further, over half of all […]
Why the FDA’s New Plausible Mechanism Pathway Demands a Data Revolution
FDA’s proposed Plausible Mechanism Pathway for bespoke therapies implicitly assumes a robust real‑world data (RWD) and real‑world evidence (RWE) ecosystem 1, even though the article only briefly names it in the context of postmarketing commitments. That ecosystem can be leveraged far earlier in development to de‑risk first‑in‑human interventions, enrich tiny trials, and create cumulative evidence […]
The Three Pillars of High-Impact AI in Rare Diseases & Oncology
For rare diseases and oncology, where data is scarce and patients are hard to find, the margin for error is razor-thin. We believe achieving success with AI requires a strategic commitment to three core pillars: The Right Data Foundation with Integrated Patient Data™: Finding quality data in Oncology & Rare Diseases has always been a […]
Enhancing FDA’s Patient-Focused Drug Development: Leveraging Clinakos’ Integrated Patient Data™ and Medically Smart AI™ for a Competitive Advantage
As the pharmaceutical industry transitions to a patient-centric model, real-world data is increasingly used to inform drug development and regulatory decisions. Including the perspectives of patients, caregivers, and advocates in drug development enhances clinical trial design, endpoint selection, and regulatory review processes. This strategy, where patient voice is not an afterthought, aims to focus research […]
